WuXi PharmaTech

WuXi opening offices in Boston and San Francisco

Monday, December 22, 2014 02:13 PM

CRO WuXi PharmaTech (Cayman), an open-access R&D capability and technology platform company with operations in China and the U.S., will open offices in Boston and San Francisco in early 2015.

More... »


WuXi AppTec launches enhanced genomics services for Chinese researchers

Monday, December 1, 2014 12:39 PM

WuXi PharmaTech, an open-access R&D capability and technology platform company serving the pharma, biotech and medical device industries with operations in China and the U.S., has announced an enhancement to its genomics services. The WuXi Genome Center will provide Chinese researchers who use its gene sequencing services with access to the integrated sequence analysis capabilities of NextCODE Health, a bioinformatics company based in Cambridge, Mass.

More... »


WuXi PharmaTech acquires XenoBiotic Laboratories

Wednesday, October 1, 2014 01:11 PM

CRO WuXi PharmaTech, with operations in China and the U.S., has acquired XenoBiotic Laboratories (XBL), a CRO with facilities in New Jersey and China. Financial terms have not been disclosed.

More... »

FDA approves WuXi’s manufacture of ibalizumab in China for use under a U.S. IND

Wednesday, May 7, 2014 01:32 PM

The FDA has approved the first batch of the ibalizumab (TMB-355) drug substance and sterile drug product, manufactured at WuXi PharmaTech's biologics facilities and developed by TaiMed Biologics for the treatment of HIV/AIDS infection. 

More... »

WuXi PharmaTech invests in TruTag security platform for drug safety

Monday, April 7, 2014 12:36 PM

CRO WuXi PharmaTech, with operations in China and the U.S., and TruTag Technologies, developer of an edible, covert security platform to address the global product counterfeiting challenge, have announced that WuXi Corporate Venture Fund has made an investment in TruTag.

More... »

WuXi PharmaTech, Pharmacyclics to partner

Monday, November 18, 2013 01:48 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its subsidiary Shanghai SynTheAll (STA) Pharmaceutical has entered into a supply arrangement with Pharmacyclics. This follows a successful multiple-year development and clinical manufacturing partnership that supported Pharmacyclics with an expedited NDA submission and final approval by the FDA of Imbruvica  on Nov. 13, for treatment of patients with mantle cell lymphoma who have received at least one prior therapy.  This indication is based on overall response rate. An improvement in survival or disease-related symptoms has not been established. 

More... »

WuXi’s genomics clinical laboratory receives CLIA certification

Monday, October 21, 2013 01:32 PM

CRO WuXi PharmaTech, with operations in China and the U.S., said its genomics clinical laboratory in Shanghai has successfully passed the survey by the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services relating to CLIA (Clinical Laboratory Improvement Amendments) standards, thereby receiving CLIA certification. WuXi's laboratory is the only CLIA-certified clinical laboratory in China.

More... »

The CenterWatch Monthly, August 2013

Friday, August 2, 2013 10:36 AM

Will end-to-end outsourcing take hold?

More... »

Ambrx, Zhejiang Medicine, WuXi PharmaTech collaborate

Tuesday, June 18, 2013 09:32 AM

Ambrx, a clinical stage biopharmaceutical company, and China-based pharmaceutical Zhejiang Medicine (ZMC) are collaborating to develop and commercialize ARX788, Ambrx’s internally developed, site-specific antibody drug conjugate (ADC) targeting Her2-positive breast cancer.

More... »

WuXi PharmaTech, PRA form joint venture for Chinese market

Thursday, December 20, 2012 10:32 AM

CRO WuXi PharmaTech, with operations in China and the U.S., and CRO PRA have signed a joint venture agreement to offer a broad platform of phase I-IV clinical trial services in China, Hong Kong and Macau, including clinical trial monitoring, project management, regulatory strategy and submissions, data management, biostatistics, drug safety reporting and medical monitoring.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 22

DaVita combines its two research CRO units to create an end-to-end CRO focused on kidney, end-stage renal disease

New crop of clinical trial matching services use patient’s molecular, genomic data for better fit

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs